# PRAISE-U pilot in Lower Silesia detects 38% clinically significant prostate cancers

- Published: 2026-11-06 09:52 UTC
- Section: Life & Health › Medicine
- Tags: PRAISE-U project, prostate cancer screening, EAU algorithm, prostate specific antigen, Lower Silesia
- URL: https://realtech.media/news/rt-76e0198bd5d46ad16937736d_praise_u_pilot/

**Over 4.6 thousand men underwent risk-stratified prostate cancer screening, resulting in 38% of detected tumors requiring treatment.**

![PRAISE-U pilot in Lower Silesia detects 38% clinically significant prostate cancers](https://sgzwpqqelzmajkcubgkl.supabase.co/storage/v1/object/public/rt-media/2026/11/7679376b6cb8cff3.jpg)
*Goleisureintl, Wikimedia Commons, CC BY 4.0*

Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii tested over 4.6 thousand men aged 50–69 in Lower Silesia as part of the European PRAISE-U project, according to Nauka w Polsce [1]. The initiative evaluates organized prostate cancer screening protocols designed by the European Association of Urology (EAU). Across the local cohort, 38% of all detected malignancies were clinically significant lesions requiring therapy [1].

The pilot sent approximately 53 thousand personal invitations, reaching participants via family physicians, local community actions, and a specialized mobile medical vehicle [1]. Overall, PRAISE-U spans an almost three-year effort across 25 institutions in 12 countries, with testing sites also located in Ireland, Lithuania, and Spain [1].

## Risk stratification protocol

The diagnostic algorithm begins with a blood test measuring prostate-specific antigen levels [1]. If the measurement exceeds 3 ng/ml, the patient enters an individualized risk assessment to determine the necessity of magnetic resonance imaging [1]. Biopsy is reserved exclusively for participants whose imaging and analytical data indicate the highest danger level [1].

Patients evaluated as low-risk despite elevated antigen levels avoid immediate imaging and biopsies, receiving a recommendation for a follow-up test in two years [1]. In Lower Silesia, 43% of participants with elevated antigen readings were categorized as low risk [1].

## Diagnostic accuracy and expansion

Among the biopsies conducted in the Polish cohort, 75% confirmed the presence of prostate cancer [1]. Across all European pilot sites, biopsies were performed in only one out of five men with elevated PSA levels, and nearly three-quarters of those procedures confirmed a malignancy [1]. The share of clinically significant tumors across Europe ranged from 19% in Lithuania to 80% in Galicia, Spain [1].

The initiative will continue under the PRAISE-U Plus phase, adding eight pilot centers across Germany, Austria, Italy, Portugal, and Slovenia [1]. Existing regional centers will advance to a second round of participant screening matched to individual risk profiles [1].

## Sources

1. [Nauka w Polsce](https://naukawpolsce.pl/aktualnosci/news%2C115791%2Cdolnoslaskie-badanie-przesiewowe-raka-prostaty-38-proc-wykrytych-nowotworow)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-76e0198bd5d46ad16937736d_praise_u_pilot/